Company intelligence / Profile preview
Innostellar Biotherapeutics
Not specified*, Jiangsu, Chinainnostellarbio.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset LX101 for hereditary retinal dystrophy is in Phase III trials in China, with prior clinical trial approval and promising early results for vision improvement. LX102 for wet AMD is in Phase II. An AIPL1 gene therapy program targeting Leber Congenital Amaurosis is preclinical.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy (AAV-based)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Clinical Research Center for Eye Diseases, Chinaclose collaborations with major hospitals and clinical scientists across China.
Beyond the preview
Go deeper on Innostellar Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innostellar Biotherapeutics.